Poster exhibition
Antiviral therapy and resistance

Programm

• • Poster
  • P 018

  First-in-class triazine-derivative is a broad-spectrum antiviral drug

  • Lisa Knandel (Berlin / DE)

   Antiviral therapy and resistance
• • Poster
  • P 020

  Candidate blockers identification for RNA dependent RNA polymerase as potential drugs for Covid-19

  • Professor Joseph Minari (Lagos / NG)

   Antiviral therapy and resistance
• • Poster
  • P 022

  Detection of the in silico, in vitro and in ovo Anti-Coronavirus Effect of Water-Soluble C60 Fullerene

  • Prof. Dr. Zinaida Klestova (Tuebingen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 023

  Increase of Synergistic Secondary Antiviral Mutations in the Evolution of A(H1N1)pdm09 Influenza Virus Neuraminidases

  • Dr. Susanne Duwe (Berlin / DE)

   Antiviral therapy and resistance
• • Poster
  • P 024

  Amitripytiline potently neutralizes the replication of distinct SARS-CoV-2 Variants

  • Isabel Nadine Zydek (Essen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 025

  Toward improved antiviral therapies: Computational meta-analysis of genome characteristics and strategy for prioritization of defective interfering particles

  • Dr. Tanja Laske (Hamburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 026

  Characterization of the in vitro antiviral activity of influenza A virus defective interfering particles using a systems biology approach

  • Patricia Opitz (Magdeburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 027

  Antiviral activity of small molecules against coronaviruses

  • Natalie Maria Köhler (Hanover / DE)

   Antiviral therapy and resistance
• • Poster
  • P 028

  Ultra-deep next generation sequencing to investigate rapid development of aciclovir-resistance mutations in herpes simplex viruses type 1

  • Lena Jaki (Freiburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 029

  Characterization of PROTAC Degraders of SARS-CoV‑2 Main Protease

  • You-Ting Chen (Brunswick / DE)

   Antiviral therapy and resistance
• • Poster
  • P 030

  In vitro Characterization of the Monoclonal Antibody L3H7 Targeting the Lassa Virus Envelope Surface Glycoprotein

  • Lena Heinrich (Marburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 031

  Bulevirtide in combination with pegylated interferon alfa-2a shows a sustained off-treatment response in the liver

  • Lena Allweiss (Hamburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 032

  An antiviral siRNA multiplex treatment reduces human parainfluenza virus infection in human lung tissue

  • Anna Zimmer (Hanover / DE)

   Antiviral therapy and resistance
• • Poster
  • P 033

  PLGA Microspheres Induce Robust T Cell Responses and Heterosubtypic Protection Against Influenza

  • Julian Volk (Tuebingen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 034

  Comparing LNP-formulated siRNA and HN inhibitor BCX2798 as separate antiviral strategies against human parainfluenza virus 3

  • Fabian Röpken (Hanover / DE)

   Antiviral therapy and resistance
• • Poster
  • P 035

  Structural insights into HEV macro domain: Implications for viral function and drug design

  • Dr. George Ssebyatika (Luebeck / DE)

   Antiviral therapy and resistance
• • Poster
  • P 036

  Host-Directed Antiviral Strategy: CDK8 Supports Cytomegalovirus Replication and Represents a Target for Intervention

  • Debora Obergfäll (Erlangen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 037

  Molecular basis for the antiviral activity of the influenza defective interfering particle "OP7"

  • Dr. Julita Piasecka (Magdeburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 038

  Establishment of high throughput screening assays for antiviral compounds against hemorrhagic fever viruses

  • Lars Frenzel (Hamburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 039

  Analysis of potential drug combinations against influenza by specifically targeting the viral polymerase

  • Bahaaeldin Alhammady (Hamburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 040

  Investigating antiviral properties of sialic acid-based compounds against human parainfluenza infections

  • Dr. Sarah Harmening (Umeå / SE)

   Antiviral therapy and resistance
• • Poster
  • P 041

  Discovery of a small molecular ligand for the Ebola virus VP30 transcription factor with antiviral activity

  • Christopher Veeck (Marburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 042

  Inhibitors of dihydroorotate dehydrogenase cooperate with 4′-Fluorouridine to inhibit RNA virus replication

  • Leon Schrell (Goettingen / DE)
  • Hannah Lena Fuchs (Goettingen / DE)
  • Professor Matthias Dobbelstein (Goettingen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 043

  Utilizing CAR T cells to fight cytomegalovirus infection in the immune compromised host

  • Sabrina Kübel (Erlangen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 044

  High-throughput screening of SAMHD1 inhibitors

  • Aleksandra Mitrić (Erlangen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 045

  Innovative Immunological Tool for the Preemptive Identification of CMV Reactivation Risk in Lung Transplant Recipients

  • Edith Katharina Johanna Plucinski (Hanover / DE)

   Antiviral therapy and resistance
• • Poster
  • P 046

  In vitro characterization and optimization of antiviral aerosol therapy against respiratory viruses

  • Elisa Raso (Giessen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 047

  Cytidin Triphosphate Synthetase Inhibitors Enhance the Antiviral Activity of N4-Hydroxycytidine Against Influenza A Virus

  • Leon Schrell (Goettingen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 048

  Electrophilic NRF2 activators restrict human coronavirus infectivity by targeting diverse host cell factors in an NRF2-independent manner

  • Dr. Fakhar Waqas (Hanover / DE)

   Antiviral therapy and resistance
• • Poster
  • P 049

  Assay development and compound screening against SFTSV L protein

  • Dr. Dominik Vogel (Hamburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 050

  Emergence of Nirsevimab- and Palivizumab-associated RSV variants

  • Dr. Toni Luise Meister (Hamburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 051

  Development and characterisation of a novel viral macrodomain (Mac1) targeting inhibitor

  • Dr. Susanne Pfefferle (Hamburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 052

  Synergistic interference with SARS-CoV-2 replication by Molnupiravir-derived N4 hydroxycytidine and inhibitors of CTP synthetase

  • Antje Dickmanns (Goettingen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 053

  Pandemic preparedness: Studying synergistic antiviral approaches against Henipaviruses

  • Dr. David Scheibner (Greifswald / DE)

   Antiviral therapy and resistance
• • Poster
  • P 054

  Mechanistic insights into inhalable antiviral siRNA for the treatment of human parainfluenza virus 3

  • Thomas Zahn (Berlin / DE)

   Antiviral therapy and resistance
• • Poster
  • P 055

  Strong suppression of Hepatitis E virus replication in infected humanized mice upon treatment with the nucleoside analog NITD008

  • Dr. Marc Lütgehetmann (Hamburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 056

  Resistance Potential of SARS-CoV-2 Against Broad-Spectrum Monoclonal Antibodies Targeting Conserved Spike Epitopes

  • Priya Kumar (Goettingen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 057

  The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication

  • Doha Al Krad (Goettingen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 058

  Targeting the Glycoprotein Complex gM/gN for Antiviral Therapy: A Novel Approach to Combat Human Cytomegalovirus (HCMV) Infections

  • Dr. Marco Thomas (Erlangen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 059

  Geno2pheno-bNAbs: Interpretable and accurate prediction of HIV-1 bNAb resistance

  • Dr. Martin Pirkl (Cologne / DE)

   Antiviral therapy and resistance
• • Poster
  • P 060

  High throughput screening on murine norovirus to identify antiviral compounds

  • Johanna Becker (Heidelberg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 061

  N6-methyladenosine modifications regulate hepatitis E virus infections

  • Dr. Mara Klöhn (Bochum / DE)

   Antiviral therapy and resistance
• • Poster
  • P 062

  Antiviral research of Crimean-Congo hemorrhagic fever virus

  • Professor Manli Wang (Wuhan / CN)

   Antiviral therapy and resistance
• • Poster
  • P 063

  The β-catenin/CREB-binding protein (CBP) inhibitor PRI-724 acts as a broad-spectrum antiviral in in vitro and ex vivo model systems

  • Dr. Tuna Toptan (Munich / DE)

   Antiviral therapy and resistance
• • Poster
  • P 064

  Characterization of a Recombinant Human Antibody Against Herpes Simplex Virus Type 1: Restoration of Effector Function to Combat Viral Escape

  • Dr. Theo Dähne (Freiburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 065

  Plasma-based disinfection of the respiratory tract to reduce Influenza A virus burden in hamster model

  • Dr. Nancy Mounogou Kouassi (Hamburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 066

  Interrupting lipid metabolism serves as a promising strategy to inhibit SARS-CoV-2 replication

  • Dr. Zoé Schmal (Hamburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 068

  Identification of Hepatitis E Virus Inhibitors

  • Mehryad Mataei (Frankfurt am Main / DE)

   Antiviral therapy and resistance